Mergers & Acquisitions - Biotechnology


Current filters:


Popular Filters

101 to 125 of 254 results

Ignyta acquires Actagene Oncology and entry into cancer personalized medicine


Privately-held US biotechnology company, Ignyta, which engages in catalyzing personalized medicine in…

Actagene OncologyBiotechnologyIgnytaMergers & AcquisitionsOncology

Merger between Intercell and Vivalis planned to complete soon


French biotech firm Vivalis (Euronext: VLS) previously-announced acquisition of Intercell (ICEL.VI) in…

BiotechnologyIntercellMergers & AcquisitionsVaccinesValnevaVivalis

Biotech industry has "implementation gap" around demonstrating the value of products under development


Ernst & Young's annual biotech report shows strong performance by major players but a challenging environment…

BiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaResearch

Ligand acquires financial rights to over 15 development programs from Selexis


US drugmaker Ligand Pharmaceuticals (Nasdaq: LGND) has acquired a portfolio of potential future milestone…

BiotechnologyLigand PharmaceuticalsMergers & AcquisitionsResearchSelexis

OPKO Health to acquire PROLOR Biotech in $480 million stock deal


Continuing on its acquisitive path, US drugmaker OPKO Health (NYSE: OPK) has signed a definitive agreement…

BiotechnologyMergers & AcquisitionsMetabolicsOPKO HealthPharmaceuticalPROLOR Biotech

Abbott Labs told it cannot acquire Russia's Petrovax Farm


The Russian government has imposed a ban on the sale of Petrovax Farm, one of Russia's leading vaccines…

Abbott LaboratoriesBiotechnologyMergers & AcquisitionsPetrovax FarmVaccines

Life Technologies acquires South Korea's KDR Biotech


USA-based Life Technologies (Nasdaq: LIFE) has acquired KDR Biotech, a leading reagents distributor based…

Asia-PacificBiotechnologyKDR BiotechLife TechnologiesMergers & Acquisitions

Resverlogix to spin-out RVX Thera to unlock epigenetics platform value


Canadian drugmaker Resverlogix (TSX:RVX), which is exploring a sale, says that its board of directors…

ApolipoproteinBiotechnologyImmunologicalsMergers & AcquisitionsOncologyResverlogixRVX TherapeuticsRVX-208

OriGene to acquire SDIX' Life Science business assets


Privately-held OriGene Technologies, a genome wide product company for research and diagnostic applications…

BiotechnologyMergers & AcquisitionsOriGene TechnologiesSDIX

Two life sciences IPOs and strengthening markets offer encouragement to Biotech sector


Two companies focused on infectious disease successfully completed initial public offerings (IPOs) in…

BiotechnologyFinancialLicensingMergers & Acquisitions

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X


In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

Briefs: Biogen Idec gets new Tecfidera patent; Fresenius Kabi to buy Indian facility


US biotech firm Biogen Idec (Nasdaq: BIIB) yesterday announced that the US Patent and Trademark Office…

BG-12Biogen IdecBiotechnologyFresenius KabiMergers & AcquisitionsParenteral Drugs IndiaPatentsProductionTecfidera

Shire acquires Premacure to expand in new therapy area


In a second acquisition so far this year, Ireland-headquartered drugmaker Shire (LSE: SHP) said on Tuesday…

BiotechnologyMergers & AcquisitionsOphthalmicsPharmaceuticalPremacureRare diseasesShire

Elan to unlock benefits for shareholders from Tysabri deal


The board of Ireland-based drugmaker Elan Corp (NYSE:ELN) has approved the decision to initiate a unique…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsPharmaceuticalRoyalty PharmaTysabri

Bone Therapeutics invests in state-of-the-art cell therapy manufacturing facility and SCTS


Belgium-based biopharmaceutical company Bone Therapeutics, focused on innovative cell therapy products…

BiotechnologyBone TherapeuticsEuropeFinancialMergers & AcquisitionsPreobProductionSkeletal Cell Therapy Support

Tranzyme exploring options, including sale of the firm; is Ache up for sale?


Following two recent R&D pipeline disappointments, the board of directors of US biotech firm Tranzyme…

Ache Laboratorios FarmaceuticosBiotechnologyMergers & AcquisitionsNorth AmericaPharmaceuticalSouth AmericaTranzyme

Elan sells its Tysabri rights to Biogen; posts 2012 financials


Ireland-based drugmaker Elan Corp (NYSE: ELN) said yesterday that partner US biotech firm Biogen Idec…

Biogen IdecBiotechnologyElanFinancialMergers & AcquisitionsNeurologicalPharmaceuticalTysabri

101 to 125 of 254 results

Company Spotlight



Back to top